Monday, November 1, 1993
Sandoz's nimble approach to biotech development
Frustrated at the slow pace at which GM-CSF was developed, Sandoz Pharmaceuticals Corp.
is proving that a streamlined biopharmaceutical operation within the parent company can
save money and move fast.
Sandoz's Cytokine Development Unit was started in August 1991 to develop therapies for
cancer and cancer-related disorders. The CDU's first budget combined the previous budgets
of its component parts and slashed them by a third based on presumed economies. In the
CDU's first full year of operations in 1992, it came in 15 percent under budget, according
to Daniel Levitt, executive director. The budget was increased this year, but will come in
15 percent under budget again.
"The CDU grew out of the perception that the development of GM-CSF didn't go well
within Sandoz, and that the